PF-Atlas › Clinical Trials › NCT05570058
Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis
RXC007 · Phase 2
Registry ID
NCT05570058
Phase
Phase 2
Status
Active, not recruiting
Drug / intervention
RXC007
Sponsor
Redx Pharma Ltd
Start
2022-09-08
About this trial
RXC007 is evaluated in NCT05570058, a Phase 2 idiopathic pulmonary fibrosis study sponsored by Redx Pharma Ltd. Current status: Active, not recruiting.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT05570058 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.